We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardiovascular Systems Innovation On Track, Competition Rife
Read MoreHide Full Article
On Jun 6, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. . The company is a medical device manufacturer that develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases, including those with arterial calcium.
Cardiovascular Systems has been trading above the Zacks classified broader Medical-Product industry in most of last three months. An impressive third-quarter 2017 result, with earnings and sales ahead of the Zacks Consensus Estimate, has further boosted the share price.
Over this period, the stock has gained 16.5%, way higher than broader industry’s 6.8%. We are also encouraged by the company’s improving operating expense scenario, driving a year-over-year rise in the earnings. Per management, the company delivered an enhanced revenue growth, moving toward positive cash flow and profitability.
Notably, Cardiovascular Systems has been conducting multiple clinical trials with an aim to display the efficacy of its technology. This has allowed physicians to select the company’s products to offer best treatment options to their patients.
Recently, the company released 1-year results from its Coronary Orbital Atherectomy System Study (COAST) in a late-breaking presentation. It also presented a six-month data from its LIBERTY 360° post-market study. The trial evaluated some acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in treating patients with symptomatic lower extremity peripheral artery disease (PAD).
On the flip side, Cardiovascular Systems operates in competitive medical device industry, which gets significantly affected by new product introductions. Thus failure to expand business overseas might hamper growth.
Currently its revenues are derived from domestic operations. However, the company plans to start selling internationally in future and has already commenced the process of seeking approval for commercial sales in both Europe and Japan. Nevertheless, uncertainty with regard to regulatory approvals and sales potential has been impacting operations in international markets.
Zacks Rank & Better Key Picks
Cardiovascular Systems currently carries a Zacks Rank #3 (Hold). Few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 22.8%. The stock has roughly added 44.3% over last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 78.3%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 13.7% over last three months.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardiovascular Systems Innovation On Track, Competition Rife
On Jun 6, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. . The company is a medical device manufacturer that develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases, including those with arterial calcium.
Cardiovascular Systems has been trading above the Zacks classified broader Medical-Product industry in most of last three months. An impressive third-quarter 2017 result, with earnings and sales ahead of the Zacks Consensus Estimate, has further boosted the share price.
Over this period, the stock has gained 16.5%, way higher than broader industry’s 6.8%. We are also encouraged by the company’s improving operating expense scenario, driving a year-over-year rise in the earnings. Per management, the company delivered an enhanced revenue growth, moving toward positive cash flow and profitability.
Notably, Cardiovascular Systems has been conducting multiple clinical trials with an aim to display the efficacy of its technology. This has allowed physicians to select the company’s products to offer best treatment options to their patients.
Recently, the company released 1-year results from its Coronary Orbital Atherectomy System Study (COAST) in a late-breaking presentation. It also presented a six-month data from its LIBERTY 360° post-market study. The trial evaluated some acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in treating patients with symptomatic lower extremity peripheral artery disease (PAD).
On the flip side, Cardiovascular Systems operates in competitive medical device industry, which gets significantly affected by new product introductions. Thus failure to expand business overseas might hamper growth.
Currently its revenues are derived from domestic operations. However, the company plans to start selling internationally in future and has already commenced the process of seeking approval for commercial sales in both Europe and Japan. Nevertheless, uncertainty with regard to regulatory approvals and sales potential has been impacting operations in international markets.
Zacks Rank & Better Key Picks
Cardiovascular Systems currently carries a Zacks Rank #3 (Hold). Few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 22.8%. The stock has roughly added 44.3% over last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 78.3%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 13.7% over last three months.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>